{
    "nct_id": "NCT03732677",
    "official_title": "A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.",
    "inclusion_criteria": "Inclusion:\n\n* Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology\n* Patients must be planning to undergo a radical cystectomy\n* Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC\n* ECOG performance status of 0 or 1\n* Must have a life expectancy of at least 12 weeks at randomization\n\nExclusion:\n\n* Evidence of lymph node (N2-N3) or metastatic (M1) disease at time of screening.\n* Prior pelvic radiotherapy treatment within 2 years of randomization to study\n* Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti PD-L1, or anti-PD-L2 antibodies.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.\n* Uncontrolled intercurrent illness\n* Active infection including Tuberculosis, Hepatitis B, Hepatitis C, and Human Immunodeficiency\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}